Neil Cashman's most recent trade in ProMIS Neurosciences Inc. was a trade of 15,000 Common Shares done at an average price of $1.0 . Disclosure was reported to the exchange on Feb. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ProMIS Neurosciences Inc. | Neil Cashman | Director, Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 10 Feb 2025 | 15,000 | 16,617 | - | 1.0 | 14,595 | Common Shares |
| ProMIS Neurosciences Inc. | Neil Cashman | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2024 | 200,000 | 200,000 | - | - | Option (right to buy) | |
| ProMIS Neurosciences Inc. | Neil Cashman | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 10,643 | 113,304 | - | - | Common Shares | |
| ProMIS Neurosciences Inc. | Neil Cashman | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 10,643 | 10,643 | - | - | Warrants to purchase Common Shares |